This study is testing a new treatment combination for people recently diagnosed with glioblastoma (a type of brain cancer). It combines the Optune® device (which uses electric fields to fight cancer) with two medications: temozolomide (a chemotherapy drug) and pembrolizumab (an immunotherapy drug). Some participants will receive Optune®, temozolomide, and pembrolizumab, while others will receive Optune®, temozolomide, and a placebo (an inactive substance). The main goal is to see if this combination improves overall survival (how long people live). You may be able to join if you are 18 or older and have a new diagnosis of glioblastoma. The study plans to enroll 741 participants, but its current status is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study with two groups, planning to enroll 741 participants. This means you would be randomly assigned to one of two treatment groups, and neither you nor your doctors would know which group you are in.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure overall survival at 24 months, indicating a follow-up period of at least two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.